23.04.2025 • News

From Innovation to Implementation

What happens when over 300 pharmaceutical leaders from across Europe and beyond gather in Berlin? Insightful discussions, strategic collaboration and opinions exchange — all under one roof. The 5th edition of the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP), held on 14–15 April, brought together decision-makers from across the pharmaceutical value chain to explore the technologies, trends and innovations shaping drug production and packaging.

PHARMAP 2025 provided insightful perspectives on the latest trends in pharmaceutical manufacturing, sustainability, automation, and digital transformation. The conference showcased the industry’s ongoing innovation and highlighted emerging challenges and solutions shaping the future of pharma.

The event welcomed leading global players, including Sandoz, Merck, Novartis, Bayer, Takeda, F. Hoffmann-La Roche, and Almirall S.A., among many others. As the industry navigates a period marked by cost pressures, regulatory evolution, and increasing demand for sustainability and digitalisation, the Congress provided a business programme full of peer-level exchange, insights, and practical solutions.

The 5th-anniversary edition was proudly supported by CryoXpert – the medical division of Dohmeyer – as the Principal Sponsor. A longstanding partner of the Congress, CryoXpert was represented by Frans Mortier, Strategic Sales Manager, who delivered a welcome speech during the opening panel.

He also participated in a session on efficiency in pharmaceutical manufacturing. His presentation focused on the rapid development of mRNA-based therapies, outlining the operational shifts required to move from clinical trials to commercial launch. Key points included the importance of regulatory alignment, manufacturing scale-up, and supply chain preparedness in supporting the wider adoption of mRNA technologies. The list of speakers in this session also contained:

  • Björn-Thoralf Erxleben, Senior Manager Market Manager Pharma & Biopharma at Shimadzu Europa
  • Antonella Cimatti, CDMO Strategic Account Manager - Morpho, and Giovina Di Meo, Project & Product Lifecycle Management Office Coordinator at Alfasigma
  • Devendra Ridhurkar, СEO at RidNova Pharmaceuticals
PHARMAP 2025 in Berlin
PHARMAP 2025 in Berlin
© BGS Group

Sustainability also featured prominently in the PHARMAP 2025 agenda. During the opening panel, Stanislav Kazanov, Head of Sustainability at Innowise, delivered an insightful presentation on digital intelligence in green drug manufacturing. He presented case studies showing how pharmaceutical manufacturers have reduced energy consumption and decreased waste through IoT-based monitoring and AI-driven insights. The presentation included implementation strategies and ROI analysis of successful deployments. The topics of the session also referred to:

  • digital transformation of drug manufacturing and packaging - presented by Thierry Marchal, Chief Technologist Healthcare EMEA at Ansys
  • strategies for ensuring safe medicines - shown by Chakravarthi AVPS, Global Ambassador at the World Packaging Organisation
  • emerging challenges in pharmaceutical manufacturing - delivered by Ayse Hizli, Director of New Business and Global Partnerships Strategy at Sandoz
  • evolving dynamics of the global supply chain - illustrated by Ton Knipscheer, Executive Director at ECPA (European Co-Packers Association)

The 5th PHARMAP Congress reinforced its role as a dedicated platform for knowledge exchange, strategic alignment, and innovation within pharmaceutical manufacturing and packaging.

The next edition of PHARMAP is scheduled for 20–21 April in Amsterdam, the Netherlands. In 2026, PHARMAP will continue to operate in a closed-door format, fostering a focused and confidential environment for high-level dialogue. The agenda explores how pharmaceutical manufacturers can strike a balance between functionality, safety, and brand integrity, what defines a win-win partnership, and how to take personalised medicine to the next level.

To secure a place now: PHARMAP 2026

Company

BGS Group



Netherlands

Company contact







Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

Artificial Intelligence

Pierre Racz: "Real Artificial Intelligence Does Not Exist"
part one of a three-part interview series

Pierre Racz: "Real Artificial Intelligence Does Not Exist"

In part one Pierre Racz, President of Genetec, is addressing why IP network video systems were the game changer in the industry and why he does not like the term AI.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
27.03.2025 • News

Moeve Joins Global Impact Coalition

The Global Impact Coalition (GIC), a collaborative platform led by CEOs and focused on achieving a net-zero chemicals future, has announced the addition of Moeve as its newest member.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.